EichorEICHOR
Condition: Her2 Negative Metastatic Breast Cancer Synced from ClinicalTrials.gov · August 09, 2026

Recruiting studies: Her2 Negative Metastatic Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast
Phase 2 · 2 location(s) · University of Washington · NCT06179303Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1 · 1 location(s) · SAPU NANO (US) LLC · NCT07369505Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Phase 2 · 9 location(s) · Institut Curie · NCT07193394Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Brea
Phase 2/Phase 3 · 9 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05744687Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · 24 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Brea
Phase 1 · 3 location(s) · Dana-Farber Cancer Institute · NCT06488378Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961ctDNA-guided Treatment Decision-making
Phase 2 · 1 location(s) · Fudan University · NCT07394218A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07612891A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Hi
Phase 1/Phase 2 · 3 location(s) · University of Southern California · NCT04333706Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 3 location(s) · Icahn School of Medicine at Mount Sinai · NCT05095207Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Phase 3 · 3 location(s) · Shanghai Yizhong Pharmaceutical Co., Ltd. · NCT06143553Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NA · 1 location(s) · Brigham and Women's Hospital · NCT04030507Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07258108SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Phase 1 · 2 location(s) · General Oncology, Inc. · NCT04150042Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04923542Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07486089Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
Phase 2 · 1 location(s) · University of California, San Diego · NCT07227233A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT06907043DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Phase 2 · 1 location(s) · Laura Huppert, MD, BA · NCT06224673A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Phase 1 · 18 location(s) · Totus Medicines · NCT05683418ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin
Phase 1/Phase 2 · 1 location(s) · Kristina A. Fanucci · NCT07198724Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastat
NA · 1 location(s) · Washington University School of Medicine · NCT04968964A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients Wit
Phase 1/Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06508216DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Phase 2 · 3 location(s) · Nancy Lin, MD · NCT06176261Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Phase N/A · 1 location(s) · University of California, San Francisco · NCT06774027TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Phase 2 · 11 location(s) · Ana C Garrido-Castro, MD · NCT06533826Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Phase 1/Phase 2 · 10 location(s) · SynDevRx, Inc. · NCT05455619OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3 · 233 location(s) · Olema Pharmaceuticals, Inc. · NCT06016738
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.